Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Manuel Vadillo-Buenfil
Observed names:
M Vadillo-Buenfil,
M VadilloBuenfil,
M. Vadillo-Buenfil,
M. Vadillo-buenfil,
M. Vadillo‐Buenfil
Institutions:
Mexican Social Security Institute,
Centro Médico Nacional La Raza
Observed institutions:
Tulane University,
Mexican Social Security Institute,
Veterans Health Administration,
Centro Médico Nacional La Raza
OpenAlex ID:
A5065367273
Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II
1997
·
A. Jungwirth
, J. Pinski
, et al.
·
European Journal of Cancer
·
110
Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.
1996
·
G Halmos
, A V Schally
, et al.
·
Proceedings of the National Academy of Sciences
·
105
Responses to the antagonistic analog of LH‐RH (SB‐75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer
1994
·
David Gonzalez‐Barcena
, M. Vadillo‐Buenfil
, et al.
·
The Prostate
·
91
Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone
1997
·
A Jungwirth
, AV Schally
, et al.
·
British Journal of Cancer
·
86
PDF
Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats
1996
·
J Pinski
, N Lamharzi
, et al.
·
Endocrinology
·
82
PDF
Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH)
1996
·
J Pinski
, A Schally
, et al.
·
International Journal of Oncology
·
65
Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord
1995
·
David Gonzalez-Barcena
, Manuel Vadillo-Buenfil
, et al.
·
Urology
·
60
Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs
1999
·
Karoly Szepesházi
, Gabor Halmos
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
47
Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis.
2003
·
Griselda Galindo-Rodríguez
, Reyna Bustamante
, et al.
·
PubMed
·
29
[Analysis of Bcr-abl type transcript and its relationship with platelet count in Mexican patients with chronic myeloid leukemia].
2003
·
Alejandro Rosas-Cabral
, Manuel Martínez-Mancilla
, et al.
·
PubMed
·
22
Long-term effectiveness of danazol corticosteroids and cytotoxic drugs in the treatment of hematologic manifestations of systemic lupus erythematosus
2003
·
J A Avina-Zubieta
, G Galindo-Rodri'guez
, et al.
·
Lupus
·
20
Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3 + and CD4 + lymphocytes
2004
·
J. Vela-Ojeda
, M. A. Garc�a-Ruiz Esparza
, et al.
·
Annals of Hematology
·
12
IFN- α as Induction and Maintenance Treatment of Patients Newly Diagnosed with Waldenström's Macroglobulinemia
2002
·
J. Vela-Ojeda
, M.A. García-Ruiz Esparza
, et al.
·
Journal of Interferon & Cytokine Research
·
3
Efecto de la infusión intraduodenal de lidocaína sobre pancreatitis aguda experimental
2008
·
Jesús Arenas-Osuna
, D. Salazar-Exaire
, et al.
·
Cirugía y Cirujanos
·
1
Caracterización de los receptores de membrana celular para hormonas peptídicas en el tejido prostático
2003
·
Manuel Vadillo-Buenfil
·
Gaceta Médica de México
Show more works
View as search
Works count:
15
Citation count:
733
H-index:
12
I10-index:
12
Year
Topic
Type